{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:44:54Z","timestamp":1765547094103},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The coronavirus disease 2019 (COVID-19) was classified as a pandemic in March 2020 by the World Health Organization. The Pfizer-BioNTech COVID-19 vaccine was the first to be authorized in the European Union, based on data from phase 1, 2, and 3 clinical trials of limited duration. Concerns have been raised regarding the vaccine's safety profile. Some of the adverse drug reactions (ADRs) associated with vaccines may not have been identified during clinical trials. This study aimed to identify ADRs associated with the Pfizer-BioNTech vaccine in health care professionals at a Portuguese tertiary university hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The data used in this analysis consist of ADRs reported through a spontaneous notification system from vaccines administered between December 27, 2020, and January 31, 2021. ADRs were categorized according to the MedDRA terminology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 8,605 Pfizer-BioNTech vaccines were administered to 4568 health care professionals. ADRs were reported among 520 of the vaccines, with an incidence of 13.56% in women and 5.31% in men. The mean age of the population reporting ADRs was 41.52 years, with a standard deviation of 9.83 years. The most frequent ADRs were myalgia (n = 274), headache (n = 199), pyrexia (n = 164), injection site pain (n = 160), fatigue (n = 84), nausea (n = 81), chills (n = 65), lymphadenopathy (n = 64), and arthralgia (n = 53). Hypersensitivity reactions occurred in 15 health care professionals, with no anaphylactic reactions observed. A total of four Important Medical Events were observed, which consisted of two cases of syncope, one case of sudden hearing loss, and one case of transverse myelitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The vaccine was well-tolerated among the study participants. Reactogenicity was greater after the second dose. The incidence of ADRs was higher in women and individuals aged between 40 to 49 years. Systemic adverse reactions were most frequently reported. Systematic monitoring of ADRs of COVID-19 vaccines in real-life context is essential for a more robust establishment of its safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000219","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T18:04:51Z","timestamp":1687802691000},"update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Spontaneous reporting of adverse reactions associated with the COVID-19 vaccine in health care professionals: A descriptive observational study conducted in a Portuguese hospital"],"prefix":"10.1097","volume":"8","author":[{"given":"Vanessa S. G.","family":"Te\u00f3filo","sequence":"first","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo R. A.","family":"Pinho","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gon\u00e7alo J.","family":"Cordeiro","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno A. F.","family":"Saldanha","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro M. M.","family":"Matos","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui A. M.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salom\u00e9 M.","family":"Moreira","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana S. F","family":"Miller","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia R. M.","family":"Dias","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta F. R.","family":"Couto","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro M. P. N. S.","family":"Norton","sequence":"additional","affiliation":[{"name":"Occupational Health Service, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5]]},"reference":[{"key":"R1-20241001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40267-021-00852-z","article-title":"Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems","volume":"37","author":"Shrestha","year":"2021","journal-title":"Drugs Ther Perspect"},{"key":"R2-20241001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01744-7","article-title":"The COVID-19 vaccine race: challenges and opportunities in vaccine formulation","volume":"21","author":"Wang","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"R3-20241001","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"key":"R4-20241001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12941-020-00384-w","article-title":"SARS-CoV-2\/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic","volume":"19","author":"Rabaan","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"27","key":"R11-20241001","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"R12-20241001","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14740338.2020.1807003","article-title":"Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis","volume":"19","author":"Paudyal","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R13-20241001","doi-asserted-by":"crossref","first-page":"2042098620922480","DOI":"10.1177\/2042098620922480","article-title":"Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal","volume":"11","author":"Shrestha","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"9","key":"R17-20241001","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/ph14090873","article-title":"Side effects of mRNA-based COVID-19 vaccine: Nationwide phase IV study among healthcare workers in Slovakia","volume":"14","author":"Riad","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R18-20241001","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3346\/jkms.2021.36.e115","article-title":"Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea","volume":"36","author":"Bae","year":"2021","journal-title":"J Korean Med Sci"},{"key":"R19-20241001","doi-asserted-by":"crossref","first-page":"760047","DOI":"10.3389\/fmed.2021.760047","article-title":"BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees","volume":"8","author":"Alghamdi","year":"2021","journal-title":"Front Med"},{"key":"R20-20241001","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA"},{"key":"R21-20241001","doi-asserted-by":"crossref","first-page":"2100634","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100634","article-title":"Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England","volume":"26","author":"Powell","year":"2021","journal-title":"Euro Surveill"},{"key":"R22-20241001","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm10071428","article-title":"Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic","volume":"10","author":"Riad","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"R23-20241001","doi-asserted-by":"crossref","first-page":"e2140364","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"R24-20241001","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"R26-20241001","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jiac.2022.03.015","article-title":"Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers","volume":"28","author":"Maruyama","year":"2022","journal-title":"J Infect Chemother"},{"issue":"5","key":"R28-20241001","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamapediatrics.2022.0088","article-title":"Hypersensitivity reactions to COVID-19 vaccines\u2014identify high-risk children and vaccinate the rest","volume":"176","author":"Fernandez-Davila","year":"2022","journal-title":"JAMA Pediatr"},{"key":"R29-20241001","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20241001","doi-asserted-by":"crossref","first-page":"100074","DOI":"10.1016\/j.nerep.2022.100074","article-title":"Transverse myelitis as a first event of multiple sclerosis precipitated by Pfizer-BioNTech COVID-19 vaccination","volume":"2","author":"Guarnaccia","year":"2022","journal-title":"Neuroimmunology Rep"},{"issue":"12","key":"R31-20241001","first-page":"e20460","article-title":"Incomplete subacute transverse myelitis following vaccination with Pfizer-BioNTech COVID-19 mRNA vaccine: a case report","volume":"13","author":"Alabkal","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"R32-20241001","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00415-021-10785-2","article-title":"Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature","volume":"269","author":"Khan","year":"2022","journal-title":"J Neurol"},{"key":"R33-20241001","article-title":"A rare case of longitudinally extensive transverse myelitis following Pfizer-BioNTech COVID-19 vaccination with a favourable outcome","volume":"9","author":"KC","year":"2022","journal-title":"EJCRIM"},{"issue":"2","key":"R34-20241001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/jamaoto.2022.4154","article-title":"Sudden hearing loss following vaccination against COVID-19","volume":"149","author":"Nieminen","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"R35-20241001","doi-asserted-by":"crossref","first-page":"101595","DOI":"10.1016\/j.pmedr.2021.101595","article-title":"Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia","volume":"24","author":"Almohaya","year":"2021","journal-title":"Prev Med Rep"},{"key":"R36-20241001","first-page":"1","article-title":"Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021","author":"Ossato","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"R37-20241001","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/biology10080752","article-title":"Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers","volume":"10","author":"Klugar","year":"2021","journal-title":"Biology"},{"key":"R38-20241001","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2147\/IJGM.S310497","article-title":"Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study","volume":"14","author":"El-Shitany","year":"2021","journal-title":"Int J Gen Med"},{"key":"R39-20241001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jiac.2021.09.009","article-title":"Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers in Japan","volume":"28","author":"Saita","year":"2022","journal-title":"J Infect Chemother"}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:02:45Z","timestamp":1727809365000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000219","relation":{},"ISSN":["2444-8664"],"issn-type":[{"type":"electronic","value":"2444-8664"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2023-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}